Close
What would you like to look for?

19 January 2023

The AMR Action Fund, the world's largest public-private partnership investing in biotech companies that are developing antimicrobials, has invested in BioVersys AG, a clinical-stage company based in Basel, Switzerland. The transaction marks the Fund's first investment in Europe and is an important step toward building an international portfolio of companies that are de-veloping urgently needed antimicrobials. BioVersys AG is focusing on research and develop-ment of therapies for life-threatening multidrug-resistant bacterial infections and targeted mi-crobiome modulation. With this investment, BioVersys AG extended its Series C investment round to CHF 32.6m. VISCHER AG advised AMR Action Fund with a team lead by Matthias Staehelin with Sebastian Flückiger, Balthasar Müller and Natacha Tang (all Corporate/M&A).

Categories: Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk

Authors